<?xml version="1.0" encoding="UTF-8"?>
<p id="p0190">Another IL-6R monoclonal antibody Sarilumab is under clinical trials for SARS-CoV-2 (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04315298" id="ir0305" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04315298</ext-link>). It is widely used in the treatment of rheumatoid arthritis and it suppresses the IL6R mediated inflammation [
 <xref rid="bb0695" ref-type="bibr">139</xref>]. Cytokine storm is responsible for the pneumonia condition in SARS-CoV-2 infected patients. Clinical trials on Sarilumab and Remdesivir have been initiated to test the therapeutic efficacy against SARS-CoV-2 [
 <xref rid="bb0700" ref-type="bibr">140</xref>]. The potential therapeutic role of Sarilumab in COVID-19 need to be further confirmed in clinical conditions. The monoclonal antibodies which are under the clinical trials are represented in 
 <xref rid="t0025" ref-type="table">Table 5</xref> .
</p>
